(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Sumitomo Pharma America, Inc.
Hoffmann-La Roche
Blueprint Medicines Corporation
AstraZeneca
Daiichi Sankyo